Collagen Type I-C Telopeptide
Test Code QCTX Test Name Collagen Type I-C Telopeptide CPT Codes 82523 Expected Turnaround Time 3 - 5 days Clinical Utility For in vitro diagnostic use as an indicator of human bone resorption. This test may be used as an aid in monitoring bone resorption chan
| Test Code | ||||
| QCTX | ||||
| Test Name | ||||
| Collagen Type I-C Telopeptide | ||||
| CPT Codes | ||||
| 82523 | ||||
| Expected Turnaround Time | ||||
| 3 - 5 days | ||||
| Clinical Utility | ||||
|
For in vitro diagnostic use as an indicator of human bone resorption. This test may be used as an aid in monitoring bone resorption changes of antiresorptive therapies in postmenopausal women, individuals with osteopenia, and in predicting skeletal response (bone mineral density) in postmenopausal women undergoing antiresorptive therapies. • Hormone replacement therapies (HRT) with hormones and hormone-like drugs • Bisphosphonate therapies |
||||
| Specimen and Container Info | ||||
|
Specimen Type: Serum Collection Container: Gold Top, Serum Separator Desired Specimen Volume: 0.5 mL |
||||
| Collection Instructions | ||||
|
||||
| Processing and Submission Instructions | ||||
|
||||
| Patient Preparation | ||||
|
Morning/Fasting specimen preferred. This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample. |
||||
| Transport Instructions | ||||
|
Transport to the laboratory frozen. |
||||
| Stability Requirements | ||||
|
||||
| Methodology | ||||
| Electrochemiluminescence Immunoassay | ||||
| Reference Intervals | ||||
|
See patient report. |
||||
| Limitations | ||||
|
This test is not intended to predict the development of osteoporosis or future fracture risk. The use of this test has not been established in hyperparathyroidism or hyperthyroidism. When using the test to monitor therapy, results may be confounded in patients afflicted with clinical conditions known to affect bone resorption (eg, bone metastases, hyperparathyroidism, or hyperthyroidism). Results should be interpreted in conjunction with clinical findings and other diagnostic results and should not be used as a sole determination in initiating or changing therapy. Note: Serum values are not interchangeable with urine values. |
||||
| Alternate Names | ||||
|
||||
| Reference Lab | ||||
| Labcorp Of America Holdings | ||||
| Testing Schedule | ||||
| Monday-Friday |